Penumbra, Inc.
NYSE:PENMedical - Devices
-$2.30 today
- Market cap
- $12.64B
- Beta
- 0.70
- P/E (TTM)
- 72.6
- EPS (TTM)
- $4.36
Volume 0.21M
Average 0.50M
PEN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Penumbra, Inc.NYSE: PEN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $25.4M rose 9.4% year over year, ahead of the +1.9% change in trailing-twelve-month research & development. Sequentially, it rose 13.5% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Research & development amounted to 6.4% of revenue in FY2025, down 1.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +9.4% holds above the trailing-twelve-month pace of +1.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 89.77M USD
- Year-over-year change
- -5.3%
- 4-year CAGR
- -3.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 89.77M | -5.3% |
| FY2024 | 2024-12-31 | 94.78M | +12.3% |
| FY2023 | 2023-12-31 | 84.42M | +6.3% |
| FY2022 | 2022-12-31 | 79.41M | -24.1% |
| FY2021 | 2021-12-31 | 104.55M | — |
Research & Development vs competitors
How PEN compares with its peers on the latest reported figures
- PEN's LTM Jun 2026 research & development of $92.25M is the 7th highest of the 9 companies compared; the peer median is $1.29B.
- Its year-over-year change of +1.9% is the 7th highest of 9, against a peer median of +5.3%.
- Research & development amounts to 6.1% of revenue for PEN, versus a peer median of 8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.28B | +11.3% | +1.2% | 6.8% | |
| LTM Jul 2026 | $2.92B | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B | +17.3% | +15.8% | 10.3% | |
| LTM Sep 2026 | $1.49B | +19.2% | +14.3% | 12.9% | |
| LTM Jun 2026 | $1.09B | +3.3% | +4.5% | 16.7% | |
| LTM Sep 2026 | $96.93M | +1.0% | +8.8% | 6.0% | |
| LTM Jun 2026 | $92.25M | +1.9% | +4.2% | 6.1% | |
| LTM Feb 2026 | $27.86M | +5.7% | -5.2% | 8.9% | |
| LTM Mar 2026 | $14.1M | -9.9% | +2.1% | 5.5% | |
| Peer median (excluding PEN) | $1.29B | +5.3% | +3.3% | 8.3% | |
Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 747.59M | 847.13M | 1.06B | 1.19B | 1.4B |
| Cost of Revenue | 272.21M | 311.93M | 375.88M | 439.62M | 461.23M |
| Gross Profit | 475.38M | 535.21M | 682.64M | 755M | 942.44M |
| Gross Margin | 63.6% | 63.2% | 64.5% | 63.2% | 67.1% |
| Research & Development | 104.55M | 79.41M | 84.42M | 94.78M | 89.77M |
| Selling, General & Admin | 378.33M | 449.72M | 506.45M | 573.99M | 663.42M |
| Operating Expenses | 482.88M | 529.13M | 609.09M | 668.77M | 753.19M |
| Depreciation & Amortization | 16.41M | 24.32M | 27.26M | 23.7M | 17.47M |
| EBITDA | 7.84M | 29.96M | 108.65M | 45.99M | 223.91M |
| EBITDA Margin | 1.0% | 3.5% | 10.3% | 3.8% | 16.0% |
| Operating Income | (7.5M) | 6.08M | 73.55M | 86.22M | 189.25M |
| Operating Margin | -1.0% | 0.7% | 6.9% | 7.2% | 13.5% |
| Interest Income | 2.87M | 1.89M | 6.83M | 13.69M | 16.29M |
| Interest Expense | 1.93M | 1.75M | 1.74M | 1.42M | 1.31M |
| Other Income / Expenses | (3M) | (2.19M) | 6.1M | (65.36M) | 15.88M |
| Income Before Tax | (10.5M) | 3.89M | 79.65M | 20.87M | 205.13M |
| Pre-Tax Margin | -1.4% | 0.5% | 7.5% | 1.7% | 14.6% |
| Income Tax Expense | (13.13M) | 5.89M | (11.3M) | 6.86M | 27.44M |
| Net Income | 5.28M | (2M) | 90.95M | 14.01M | 177.69M |
| Net Margin | 0.7% | -0.2% | 8.6% | 1.2% | 12.7% |
| EPS (Basic) | 0.14 | (0.05) | 2.37 | 0.36 | 4.57 |
| EPS (Diluted) | 0.14 | (0.05) | 2.32 | 0.36 | 4.52 |
| Weighted Avg Shares | 36.76M | 37.84M | 38.4M | 38.63M | 38.92M |
| Weighted Avg Shares (Diluted) | 37.88M | 37.84M | 39.22M | 39.27M | 39.29M |
Penumbra, Inc.
NYSE:PEN
Intrinsic Alpha fair value
Locked
Current Price
$320.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.